133 related articles for article (PubMed ID: 12614037)
21. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
Arisawa H; Fukui K; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
[TBL] [Abstract][Full Text] [Related]
22. An immunohistochemistry-based study on aquaporin (AQP)-1, 3, 4, 5 and 8 in the parotid glands, submandibular glands and sublingual glands of Sjögren's syndrome mouse models chronically administered cevimeline.
Nakamura M; Saga T; Watanabe K; Takahashi N; Tabira Y; Kusukawa J; Yamaki K
Kurume Med J; 2013; 60(1):7-19. PubMed ID: 23925155
[TBL] [Abstract][Full Text] [Related]
23. Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjögren's syndrome model mice.
Nishimura H; Yakeishi A; Saga T; Yamaki K
Kurume Med J; 2009; 56(3-4):39-47. PubMed ID: 20505281
[TBL] [Abstract][Full Text] [Related]
24. A new medication for treatment of dry mouth in Sjögren's syndrome.
al-Hashimi I; Taylor SE
Tex Dent J; 2001 Apr; 118(3):262-6. PubMed ID: 11404944
[TBL] [Abstract][Full Text] [Related]
25. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
[TBL] [Abstract][Full Text] [Related]
26. Sjogren's syndrome from the perspective of ophthalmology.
Kuklinski E; Asbell PA
Clin Immunol; 2017 Sep; 182():55-61. PubMed ID: 28476437
[TBL] [Abstract][Full Text] [Related]
27. Parotid irrigation and cevimeline gargle for treatment of xerostomia in Sjögren's syndrome.
Takagi Y; Katayama I; Tashiro S; Nakamura T
J Rheumatol; 2008 Nov; 35(11):2289-91. PubMed ID: 19004065
[No Abstract] [Full Text] [Related]
28. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.
Al-Hashimi I
Drugs Aging; 2005; 22(11):887-99. PubMed ID: 16323968
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
Garlapati K; Kammari A; Badam RK; B E S; Boringi M; Soni P
Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):312-318. PubMed ID: 30932714
[No Abstract] [Full Text] [Related]
30. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations.
von Bültzingslöwen I; Sollecito TP; Fox PC; Daniels T; Jonsson R; Lockhart PB; Wray D; Brennan MT; Carrozzo M; Gandera B; Fujibayashi T; Navazesh M; Rhodus NL; Schiødt M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S57.e1-15. PubMed ID: 17379156
[TBL] [Abstract][Full Text] [Related]
31. Effect of cevimeline on salivary components in patients with Sjögren syndrome.
Suzuki K; Matsumoto M; Nakashima M; Takada K; Nakanishi T; Okada M; Ohsuzu F
Pharmacology; 2005 May; 74(2):100-5. PubMed ID: 15722648
[TBL] [Abstract][Full Text] [Related]
32. What is Sjögren's syndrome and why is it important?
Talal N
J Rheumatol Suppl; 2000 Dec; 61():1-3. PubMed ID: 11128697
[No Abstract] [Full Text] [Related]
33. [Results of the treatment with oral pilocarpine in 100 patients with primary Sjögrens syndrome].
Brito-Zerón P; Ramos-Casals M; Nardi N; Font J
Med Clin (Barc); 2006 Apr; 126(16):637. PubMed ID: 16759558
[No Abstract] [Full Text] [Related]
34. [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?].
Vamvakidès A
Ann Pharm Fr; 2003 May; 61(3):207-10. PubMed ID: 12714934
[TBL] [Abstract][Full Text] [Related]
35. Effects of cevimeline on excitability of parasympathetic preganglionic neurons in the superior salivatory nucleus of rats.
Mitoh Y; Ueda H; Ichikawa H; Fujita M; Kobashi M; Matsuo R
Auton Neurosci; 2017 Sep; 206():1-7. PubMed ID: 28600120
[TBL] [Abstract][Full Text] [Related]
36. [Sjögren's syndrome: a new approach to treatment].
Rossier V; Bart PA; Spertini F
Rev Med Suisse; 2012 Apr; 8(337):843-7. PubMed ID: 22594008
[TBL] [Abstract][Full Text] [Related]
37. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems.
Arisawa H; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642
[TBL] [Abstract][Full Text] [Related]
38. Benefits of long-term pilocarpine due to increased muscarinic acetylcholine receptor 3 in salivary glands.
Minagi HO; Ikai K; Araie T; Sakai M; Sakai T
Biochem Biophys Res Commun; 2018 Sep; 503(2):1098-1102. PubMed ID: 29953856
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome.
Noaiseh G; Baker JF; Vivino FB
Clin Exp Rheumatol; 2014; 32(4):575-7. PubMed ID: 25065774
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review.
Akpek EK; Lindsley KB; Adyanthaya RS; Swamy R; Baer AN; McDonnell PJ
Ophthalmology; 2011 Jul; 118(7):1242-52. PubMed ID: 21459453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
